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PNEUMONIA RESULT OF ZEPHyR TRIAL 
Benyamin Margono 
 
ABSTRACT 
All MRSA infections are characterized genotypically by the presence of mecA, which 
encodes for altered Pen Binding Proteins (PBP’s PBP2A) on their cell walls, giving rise to 
low affinity binding to anti-staph penicillins, resulting in phenotypically resistance to all β-
lactam antibiotics, and may also contain resistant elements for numerous antibiotic  classes: 
macrolides, lincosamides, aminoglycosides, fluoroquinolones, tetracyclines, and 
sulfonamides. Risk factors independently associated with MRSA infection are: Previous 
hospitalization within the last 12 months, late onset HAP, surgery, enteral feeding, previous 
antibiotics : Aminoglycoside (7.9 x), Levofloxacine (7.2 x), Macrolide (5 x), Vancomycin (4.3 
x), and βL βLI (2.3 x). Most guidelines for MRSA infections support the use of Vancomycin or 
Linezolid if MRSA is suspected. ZEPHyR Trial is a randomized, controlled study with ratio 
random 1:1 from linezolid  600 mg q12h IV vs vancomycin 15 mg/kg BB IV q12h until 7-14 
days, The clinical result with significancy highes for linezolid better than vancomycin, 
although mortality at 60 days did not show any difference. Linezolid showed overall safety 
and tolerability profiles were satisfactory. Summary: Indications linezolid was nosocomial 
pneumonia Staph aetiology both MSSA aureus / MRSA or Strep pneumoniae were sensitive to 
penicillin. Combination therapy when the estimated presumptive gram-negative pathogens. 
Dosage IV: oral 600 mg BID; pediatric dose: 10 mg/kg/8 hours. Duration of treatment 10-14 
days. 
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PENGEMBANGAN MANAJEMEN MRSA PNEUMONIA 
NOSOKOMIAL  HASIL UJI ZEPHyR  
 
ABSTRAK 
Semua infeksi MRSA ditandai oleh genotip mecA, yang mengkode protein pengikat 
(PBP’s, PBP2A) di dinding sel, sehingga menimbulkan penurunan afinitas dalam mengikat 
penisilin anti staphylococus, fenotipik ini berlaku untuk semua antibiotik gol β-lactam, dan 
juga dapat menjadi resisten untuk kelas antibiotik seperti: macrolides, lincosamides, 
aminoglycosides, fluoroquinolones, tetracyclines, and sulfonamides. Faktor risiko independen 
terkait dengan infeksi MRSA adalah: rawat inap 12 bulan terakhir, onset lambat dari HAP, 
pembedahan, makanan enteral, dan pemberian antibiotik  sebelumnya: aminoglycoside 
(7,9x), levofloxacine (7,2x), macrolide (5x), vancomycin (4.3x), dan βL/βLI (β-lactam/β 
lactamase inhibitor) (2,3 x). Kebanyakan pedoman infeksi mendukung penggunaan 
vancomycin atau linezolid jika dicurigai MRSA. Percobaan ZEPHyR adalah suatu studi acak 
terkontrol dengan rasio 1:1 linezolid q12h 600 mg IV vs vancomycin 15 mg / kg BB IV q12h 
selama 7-14 hari, Hasil klinis bermakna lebih baik linezolid daripada vancomycin, meskipun 
angka kematian pada 60 hari tidak menunjukkan perbedaan. Linezolid secara keseluruhan 
menunjukkan  keamanan dan profil tolerabilitas yang memuaskan. Ringkasan: Indikasi 
linezolid adalah pneumonia dengan etiologi Staphylococus aureus nosokomial baik MSSA / 
MRSA atau Streptococus pneumoniae yang sensitif terhadap penisilin. Kombinasi terapi 
diberikan bila diduga gram negatif patogen. Dosis IV sama dengan dosis oral 600 mg BID, 
dosis pediatrik: 10 mg/kg/8 jam. Lama pengobatan 10-14 hari. 
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INTRODUCTION 
The clinical presention of 
MRSA (Methicillin Resistant 
Staphilococus Pneumonia) is changing, 
healthy young people without the 
traditional risk factors for staphilococcal 
pneumonia are presenting with severe 
necrotizing infection and high mortality, 
most of which are methicillin resistant. 
All MRSA are characterized 
genotypicaly  by the presence of mecA 
which encodes for altered Penicillin 
Binding Protein (PBP‘s, PBP2A) on 
their cell walls, resulting in low affinity 
binding to antistaphilococcal penicillin, 
causing phenotypically resistance to all 
β-lactam antibiotics. They may also 
contain resistant elements to numerous 
antibiotic classes such as: macrolides, 
lincosamines, aminoglycosides, 
fluoroquinolones, tetracyclines and 
sulfonamides. 
Types of MRSA infections: 1) 
Hospital associated (nosocomial) 
MRSA infection, typically associated 
with invasive procedures and devices 
as: surgery, IV tubing, artificial joints, 
catheters etc, 2) Community acquired 
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MRSA infection, often begins as 
painful skin boil, spreading by skin to 
skin contact, forming abscesses, and can 
develop into life threatening infection of 
the blood, heart valves and lungs. 
Pathogens to consider when treating 
HAP or VAP. 
A crucial time in nosocomial 
pneumonia is day 5. HAP or VAP 
occurring before day 5 or considered 
early HAP or VAP  and those occurring 
day 5 and after are classified as late 
HAP or VAP (picture 1). 
 
 
Figure 1. : Pathogens to Consider When Treating HAP or VAP 
 
As can be seen in picture 1, MRSA is a late occurring HAP or VAP, and the 
antibiotic choice of therapy is either linezolid or vancomycin (picture 2). 
 
 
Figur 2. : Early Onset HAP and Late Onset HAP 
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RISK FACTORS 
INDEPENDENTLY ASSOCIATED 
WITH MRSA INFECTION 
Of the risk factors independently 
associated with MRSA infection, the 
graph on picture 3 is understandable. 
But the list of antibiotics on table 4 is 
worth memorizing. Topping the list 
with 7.9% is aminoglycoside, followed 
closely by levofloxacin at 7.2%, then 
macrolide at 5 %. 
 
 
 
 
Figur 3. : Risk Factors MRSA VS MSSA 
 
THE ZEPHyR TRIAL 
Is a linezolid vs vancomycin 
trial in nosocomial pneumonia. Its a 
randomized controlled study with a 
randomization ratio of 1:1. Linezolid is 
given at a dose of 600 mg q12h IV, 
while the dosage of vancomycin is 15 
mg/kg BW IV q12h with a duration of 
therapy of 7-14 days. 
 
 
Figur 4.: Study Design ZEPHyR Trial 
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RESULTS 
Clinical  success rate of 
linezolid was better than vancomycin as 
can be seen on picture 5, although 
mortality at 60 days showed no 
difference. Several risk factors 
associated with clinical failure are: 
presence of vasopressors at baseline, 
presence of cardiac co-morbidity, 
bilateral lung involvement, previous 
treatment with vancomycin, and 
presence of other pathogens at baseline 
(picture 6), 100% of the MRSA isolates 
were susceptible to linezolid ( picture 
7). 
 
 
Figur  5. : Clinical Success Rates Linezolid vs Vancomycin 
 
Figur 6. : Risk Factors Associated With Clinical Failure Linezolid vs Vancomycin 
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Figur 7. : 100% of The MRSA Isolates Were Susceptible to Linezolid 
Noteworthy is the fact that renal failure or azotemia in the linezolid arm was 
almost half that of vancomycin (figur 8). 
 
Figur 8. : Adverse Events of Interst All Causality : ITT 
 
CONCLUSION 
Conclusion of the ZEPHyR trial 
is that for the primary endpoint. Clinical 
response PP group at EOS, linezolid 
achieved a statistically significantly 
higher success rate compared to 
vancomycin. Similar results were 
observed for clinical and and 
microbiological response at EOS and 
EOT in both the PP and mITT 
populations. Overall, linezolid 
demonstrated an acceptable safety and 
tolerability profile for the treatment of 
proven MRSA nosocomial pneumonia.  
Linezolid Summary : indication 
for nosocomial pneumonia caused by 
Staph.aureus (MSSA or MRSA strains) 
or S.pneumonia penicillin susceptible 
strain only), Combination therapy 
indicated if the documented or 
presumptive pathogens include gram 
negative organisms. Dose IV=ORAL 
600 mg/bid, pediatric dose: 10 mg/kg 
BB/tid, duration of therapy 10-14 days. 
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ABSTRACT 
Optimizing outcome of antibiotic therapy entails using the appropriate antibiotic 
at the correct timing and dosing, whereas inappropriate antibiotic treatment is defined 
as inactive against target organism, delayed initiation of therapy, unnecessary 
changing of regimen, resulting in increased hospital and related mortality, length of 
stay, duration of antibiotic treatment, all leading to increased cost. In severe infection 
the strategy of early, appropiate, adequate, empirical therapy, can reduce mortality by 
50%. Use the most appropriate antibiotic, do not safe your best antibiotic for 
postmortem. Initial empiric treatment with high dose, broadspectrum antibiotic, then 
after favourable clinical assessment and culture or susceptibility data are obtained, 
switch to a more targeted narrow spectrum (de-escalation) to minimize resistance, 
toxicity and cost. Do not start low (activity and dosage) then escalate when the clinical 
effects are unsatisfactory. β-lactam antibiotics are the most frequently prescribed 
antibiotic in infections, totaling 54.4% of all antibiotics prescribed. β-lactam antibiotics 
are time dependent, meaning that Time above MIC ( T>MIC) is crucial in defining 
adequate therapy. While for clinical effectiveness : T > MIC is > 40% of the dosing 
interval, for maximum kill in severe infection with Gram (-) pathogens : T>MIC in 
excess of 70% is suggested. Continuous Infusion (CI) is a treatment strategy to reach 
this goal. CI has the potential of maintaining drug concentration at the site of infection 
over most of the dosing interval, with optimal steady state serum concentration (CSS) 
for β-lactam antibiotics : 4 x MIC. A continuous infusion of Cefepime can be prepared 
by diluting 3-4 gram of cefepime in 1 L of 5% Dextrose and given at a constant flow 
rate. Cefepime has broadspectrum antimicrobial activity against Gram (+) and Gram (-) 
pathogens, also anti pseudomonal activity. It is recommended as monotherapy in severe 
infection where pseudomonal aerugenous is probably involved, but in proven 
pseudomonal infection it is recommended that a it is combined with either an 
Aminoglycoside (Amikin) or  Quinolone ( Cipro or Levofloxacin ). 
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